Alvotech

ALVO Nasdaq CIK: 0001898416

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Large accelerated filer
State of Incorporation Luxembourg
Business Address 9, RUE DE BITBOURG, LUXEMBOURG, N4, L-1273
Mailing Address 9, RUE DE BITBOURG, LUXEMBOURG, N4, L-1273
Phone 354 422-4500
Fiscal Year End 1231
EIN 981629342

Financial Overview

FY2025

Recent SEC Filings

Form Type Date Filed Document
20-F Foreign company annual report March 31, 2026 View on SEC
6-K Foreign company current report March 19, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 12, 2026 View on SEC
6-K Foreign company current report February 27, 2026 View on SEC
6-K Foreign company current report February 5, 2026 View on SEC
6-K Foreign company current report February 2, 2026 View on SEC
6-K Foreign company current report January 29, 2026 View on SEC
6-K Foreign company current report January 7, 2026 View on SEC
6-K Foreign company current report January 7, 2026 View on SEC
6-K Foreign company current report January 6, 2026 View on SEC

Annual Reports

20-F March 31, 2026
  • Achieved first-ever annual profit of $27.9 million in 2025, signaling a successful transition to commercial operations.
  • Generated $350 million in revenue driven by the successful U.S. launch of Simlandi (AVT02).
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.